Key Takeaways
  • The guideline-backed list is short: a lipid panel, an A1C or glucose test if you're 35–70 with overweight or obesity, hepatitis C once, HIV at least once, and kidney tests if you have diabetes or high blood pressure. PSA at 55–69 is a personal decision
  • Worth asking about: Lp(a) once in your life (at least 1 in 5 people have high levels), apoB or hs-CRP to refine heart risk, iron studies if hemochromatosis runs in the family, B12 if you take metformin
  • Not routine if you feel well: vitamin D, testosterone, thyroid and multi-cancer blood tests. No multi-cancer test is FDA-approved yet; one won a favourable advisory panel vote in September 2026
  • More tests isn't automatically safer. Run 20 tests on a healthy person and there's about a 64% chance at least one comes back "abnormal"
  • Most people don't need to fast for a cholesterol test. Fasting glucose needs 8 hours without food; A1C doesn't

Turn 40 and the offers start arriving: 100-biomarker panels, hormone profiles, a single blood draw that promises to find cancer early. Some of these tests can change what you and your doctor do. Others mostly generate numbers that lead to more tests.

This guide sorts the common ones by evidence: tests guidelines recommend, tests worth raising in some situations, and tests not recommended for healthy people without symptoms. It's written for men, but nearly all of it applies to women. It isn't medical advice; take it to your doctor.

64%
Chance that a healthy person has at least one result outside the reference range when 20 independent tests are run, because each range is set to include only 95% of healthy people (Phillips, Australian Prescriber 2009)

The Tests Guidelines Back

Evidence: Strong — USPSTF and specialty guidelines

The US Preventive Services Task Force (USPSTF) weighs the benefits and harms of screening in people without symptoms, and its A and B recommendations are the nearest thing to a core list. HealthCare.gov says screening tests like these are generally covered with no copayment in-network, though "$0 cost isn't guaranteed in all cases" (HealthCare.gov).

Lipid panel

A lipid panel (total cholesterol, LDL, HDL, triglycerides) feeds your heart-risk estimate. The USPSTF's 2022 guidance covers adults aged 40 to 75 with at least one risk factor (abnormal cholesterol, diabetes, high blood pressure or smoking): at an estimated 10-year cardiovascular risk of 10% or more, start a statin (grade B); at 7.5% to under 10%, "selectively offer" one (grade C). It doesn't apply to people with an LDL above 190 mg/dL or familial hypercholesterolaemia, who need their own assessment (USPSTF, 2022).

The 2026 ACC/AHA dyslipidemia guideline recommends the newer PREVENT equations for 10- and 30-year risk in adults aged 30 to 79 (AHA). The CDC says "most healthy adults should have their cholesterol checked every 4 to 6 years," more often with heart disease, diabetes or a family history of high cholesterol (CDC).

A1C or fasting glucose

The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 with overweight or obesity (2021, grade B), using fasting glucose, A1C or a glucose tolerance test. If results are normal, "screening every 3 years may be a reasonable approach." Clinicians should consider screening earlier with a family history of diabetes or in higher-risk groups, and at a lower BMI in Asian American people (USPSTF, 2021). An A1C of 5.7% to 6.4% or fasting glucose of 100 to 125 mg/dL indicates prediabetes; 6.5% or 126 mg/dL and above, diabetes.

Hepatitis C and HIV: once is usually enough

The USPSTF recommends hepatitis C screening for all adults aged 18 to 79: an antibody test, then an RNA (PCR) test if it's positive. "Most adults need to be screened only once"; people with continuing risk, such as those who inject drugs, should be retested periodically (USPSTF, 2020).

For HIV, it gives an A grade to screening everyone aged 15 to 65, plus older adults at increased risk, with repeat tests reasonable for people at higher risk (USPSTF, 2019). An update is in progress.

Kidney tests, if you have diabetes or high blood pressure

Two tests check the kidneys: eGFR, a filtering estimate calculated from blood creatinine, and the urine albumin-to-creatinine ratio (UACR), which detects protein leaking into urine. The kidney guideline body KDIGO says to "test people at risk for and with chronic kidney disease (CKD) using both" (KDIGO 2024). The American Diabetes Association's 2026 Standards call for both at least yearly in adults with type 2 diabetes, from diagnosis, and the 2025 hypertension guideline recommends UACR testing for everyone with high blood pressure (ACC, 2026).

PSA, from 55 to 69: your call

For men aged 55 to 69, the USPSTF says "the decision to be screened for prostate cancer should be an individual one" (grade C), and it recommends against PSA screening from 70. It weighs "a small potential benefit of reducing the chance of death from prostate cancer in some men" against false positives, biopsy complications and overtreatment (USPSTF, 2018). That guidance is being updated, and we'll cover PSA in its own article.

Figure 1 · The tests at a glance

Who needs what, how often, and what to act on

TestWhoHow oftenResult worth a conversationSource
Recommended
Lipid panelAdults; drives statin decisions at 40–75Every 4–6 years if healthy; more often with heart disease, diabetes or family history10-year risk ≥10% with a risk factor (statin); 7.5% to <10% (selective) LDL >190 mg/dL needs its own assessmentUSPSTF 2022; CDC
A1C or fasting glucose35–70 with overweight or obesity; earlier with family historyEvery 3 years if normalA1C 5.7–6.4% or glucose 100–125 mg/dL (prediabetes); ≥6.5% or ≥126 (diabetes)USPSTF 2021
Hepatitis C antibodyAll adults 18–79Once; periodically with ongoing riskPositive antibody: RNA (PCR) testUSPSTF 2020
HIV15–65, older if at riskAt least once; repeat if at higher riskAny positive resultUSPSTF 2019
eGFR + urine albumin (UACR)Diabetes; high blood pressure (UACR)At least yearly with type 2 diabetesUACR ≥30 mg/g or eGFR <60, confirmed over 3+ monthsADA 2026; KDIGO 2024
PSAMen 55–69 who choose itShared decisionDiscuss any result with your doctorUSPSTF 2018
Worth asking about
Lp(a)Every adultOnce≥125 nmol/L (50 mg/dL) 75–125 nmol/L is a grey zoneEAS 2022; NLA 2024; ACC/AHA 2026
ApoBOn treatment and at LDL goal, especially with diabetes, triglycerides >200 mg/dL or LDL <70 mg/dLWith a lipid panel, when ordered≥130 mg/dL is a risk enhancer goals <90, 70 or 55 by riskACC/AHA 2018, 2026
hs-CRPSelected people, to refine heart riskSelectively≥2.0 mg/L is a risk enhancerACC/AHA 2018
Ferritin + transferrin saturationRelative with hemochromatosis; symptoms or abnormal liver testsWhen indicatedTransferrin saturation above 45%ACG 2019
Vitamin B12People taking metforminPeriodicallyLow level: discuss treatment with your doctorADA 2026
Not routine if you feel well
Vitamin DNot healthy adults—Test if a doctor suspects deficiencyUSPSTF 2021; Endocrine Society 2024
TestosteroneMen with symptoms onlyTwo early-morning testsBelow 300 ng/dL twice, plus symptomsAUA 2018; Endocrine Society 2018
TSH (thyroid)Not adults without symptoms—Repeat over 3–6 months before diagnosingUSPSTF 2015
Multi-cancer blood testsNot FDA-approved—Don't replace standard screeningACS; FDA panel 2026

Summarised from the sources listed below. Thresholds are the points at which guidelines suggest a closer look or a treatment discussion, not diagnoses on their own. Your doctor may test more often, or differently, based on your history and medicines.

Part two · Ask about

Worth Asking About

Evidence: Moderate — guideline-supported for some people

These aren't universal screening tests, but guidelines support them in specific situations.

Lipoprotein(a): one test for life

Lipoprotein(a), or Lp(a), is a lipoprotein whose level is "predominantly (>90%) determined by genetic variability." The European Atherosclerosis Society's 2022 consensus "recommends testing Lp(a) concentration at least once in adults" (Kronenberg, Eur Heart J 2022). The National Lipid Association's 2024 update agrees, estimates high Lp(a) affects "at least ∼1/5 of individuals worldwide," and classes under 75 nmol/L (30 mg/dL) as low risk, 75 to 125 as a grey zone and 125 nmol/L (50 mg/dL) or more as risk-enhancing (Koschinsky, J Clin Lipidol 2024). The 2026 ACC/AHA guideline now says to measure it at least once too, with the same 125 nmol/L threshold (AHA).

Figure 2 · UK Biobank, via EAS 2022

Median Lp(a) by ancestry, against the risk thresholds

75 125 Chinese 16 White 19 South Asian 31 Black 75 Median Lp(a), nmol/L risk-enhancing ≥125

Medians from UK Biobank, as reported in the European Atherosclerosis Society's 2022 Lp(a) consensus statement (Kronenberg et al.). Thresholds from the National Lipid Association's 2024 statement: under 75 nmol/L low risk, 75–125 grey zone, 125 or more risk-enhancing. A median means half of each group sits above it, so ancestry can't tell you your own level; one test can.

A high result means managing everything else harder: the NLA calls for "early and intensive risk factor management," and testing first-degree relatives "can identify additional individuals at risk" (NLA 2024). Our article on silent plaque, apoB and Lp(a) covers what a high result means and where the drug trials stand.

ApoB

Our plaque article explains what apolipoprotein B (apoB) measures and why it can matter when LDL looks normal. The 2026 ACC/AHA guideline says apoB testing "can be useful to improve risk assessment and guide therapy" once LDL and non-HDL cholesterol goals are met, particularly with triglycerides above 200 mg/dL, diabetes, or an LDL brought below 70 mg/dL on treatment (AHA), with goals of under 90, 70 or 55 mg/dL depending on risk (HCPLive). The 2018 guideline counted 130 mg/dL or more as a risk enhancer (AAFP summary).

hs-CRP

High-sensitivity C-reactive protein (hs-CRP) is an inflammation marker. The 2018 ACC/AHA guideline listed 2.0 mg/L or more, "if measured in selected individuals," as a risk-enhancing factor (AAFP summary), and the 2026 guideline still treats inflammatory markers that way (Quest Diagnostics). A 2025 American College of Cardiology scientific statement said "the time has come" for guidelines to adopt broad hs-CRP screening, but that's a call for change, not a guideline, and not all cardiologists agree yet (TCTMD).

Ferritin and iron, when there's a reason

Hereditary hemochromatosis, an inherited iron overload, is most common in people of Irish and Scandinavian origin. The American College of Gastroenterology says "general population screening for HH is not indicated," but recommends screening relatives, especially first-degree relatives, of anyone diagnosed, and testing people with suggestive symptoms or raised liver enzymes. The first tests are transferrin saturation and ferritin; a transferrin saturation above 45% picks up nearly everyone with the main genetic form (Kowdley, Am J Gastroenterol 2019).

Vitamin B12, if you take metformin

Metformin, a first-line drug for type 2 diabetes and prediabetes, can reduce B12 absorption, as can acid-reducers such as omeprazole (NIH Office of Dietary Supplements). The ADA's 2026 Standards link metformin to a higher risk of B12 deficiency and worse neuropathy symptoms, "suggesting periodic testing" (ADA, Diabetes Care 2026).

Tests Not Recommended for Routine Screening

Evidence: Insufficient or against — for people without symptoms

"Not recommended for screening" doesn't mean useless: each helps when a doctor is investigating symptoms. What's missing is evidence that testing people who feel well improves their health.

The cascade problem

A lab's normal range is usually set to include 95% of a healthy reference population, so 1 in 20 healthy people falls outside it on any one test. With 20 tests, "only 36% of normal people will have all 20 results in the reference range," an approximation since results aren't fully independent (Phillips, Aust Prescr 2009). Each flag can mean a repeat test, a scan or worry, and in a healthy person many are statistical noise.

Figure 3 · The arithmetic of big panels

Chance a healthy person gets at least one out-of-range result

1 test
5%
5 tests
23%
10 tests
40%
20 tests Australian Prescriber figure
64%

Assumes each reference range covers 95% of healthy people and results are independent: chance = 1 − 0.95n. The 20-test figure (64%) is from Phillips, Australian Prescriber 2009; the 1-, 5- and 10-test figures are our own calculation using the same formula. Real tests are partly correlated, so treat these as illustrations, not exact odds.

Vitamin D

The USPSTF found evidence "insufficient to assess the balance of benefits and harms of screening for vitamin D deficiency" in adults without symptoms, noting that "no one serum vitamin D level cutpoint defines deficiency" (USPSTF, 2021). The Endocrine Society's 2024 guideline goes further: "We suggest against routine testing for 25-hydroxyvitamin D levels in any of the populations studied" (Endocrine Society). Pathologists' Choosing Wisely advice agrees (ASCP).

Testosterone without symptoms

The Endocrine Society's 2018 guideline is blunt: "Men who are otherwise healthy do not need to be screened for hypogonadism." Diagnosis needs symptoms plus levels "unequivocally and consistently low," and about 30% of men with a low reading are normal on retesting (Endocrine Society). The American Urological Association uses below 300 ng/dL on two separate early-morning tests (AUA). With symptoms such as low sex drive or erectile dysfunction, testing makes sense; our TRT article covers what comes next.

Thyroid screening without symptoms

The USPSTF's 2015 finding of insufficient evidence for thyroid screening in nonpregnant adults without symptoms still stands; a 2024 scan found no new evidence to update it. It cites "frequent false-positive results" and "a large degree of overdiagnosis and overtreatment": TSH secretion "is highly variable," and many people labelled with thyroid disease drift back to normal. It advises repeating abnormal tests over 3 to 6 months (USPSTF, 2015). Symptoms are a different matter: see your doctor.

"Full-body" panels and multi-cancer blood tests

Multi-cancer early detection (MCED) tests look for signs of many cancers in one sample. The American Cancer Society says they "have not been cleared or approved by the FDA yet" and, even if approved, "do not replace current screening tests" (ACS).

That may change. On 23 September 2026 an FDA advisory panel voted 7 to 2, with one abstention, that the benefits of GRAIL's Galleri test outweigh its risks for adults 50 and over (6 to 4 on effectiveness). The FDA isn't bound by the vote and is expected to decide in the coming months (GRAIL; Oncology Nursing News).

The data cut both ways. In PATHFINDER 2, with more than 23,000 people over 50, the test flagged 216 people and 133 were diagnosed with cancer (positive predictive value 61.6%; false-positive rate 0.4%), but it found only about 4 in 10 cancers (episode sensitivity 40.4%) (Fierce Biotech). In the randomised NHS-Galleri trial of 142,250 adults aged 50 to 77, published in the New England Journal of Medicine in September 2026, stage III or IV cancers were no less common with screening (rate ratio 1.03), missing the primary endpoint; stage IV cancers were 14% lower after three rounds, not statistically significant (Oncology Learning Network). The National Cancer Institute's Vanguard Study (up to 24,000 people) is laying groundwork for a larger trial of benefits and harms (NCI).

The pitchOne blood draw screens you for dozens of cancers, or checks 100 biomarkers, so nothing gets missed.
What the evidence showsNo multi-cancer test is FDA-approved yet. Galleri found about 4 in 10 cancers, and in its largest randomised trial didn't significantly cut late-stage cancers. On paper, a 20-test panel flags at least one "abnormal" result in most healthy people. Neither replaces standard screening.
Part four · What to do

How to Ask Your Doctor

Frequently Asked Questions

What blood tests should a man get after 40?
The guideline-backed core: a lipid panel, an A1C or fasting glucose test if you're 35 to 70 with overweight or obesity, hepatitis C once (adults 18 to 79), HIV at least once (15 to 65), and kidney tests (eGFR and urine albumin) if you have diabetes or high blood pressure. PSA at 55 to 69 is a personal decision to make with your doctor.
Do I need to fast before a cholesterol test?
Usually not. The 2018 ACC/AHA guideline accepts fasting or nonfasting lipid levels for estimating risk, with a fasting repeat if nonfasting triglycerides are 400 mg/dL or higher. Some labs still ask you to fast, so check. A fasting glucose test needs at least 8 hours without food; A1C doesn't.
Should I get my Lp(a) tested?
Guidelines say yes, once. The European Atherosclerosis Society, the National Lipid Association and the 2026 ACC/AHA guideline all say to measure lipoprotein(a) at least once in adulthood. It's more than 90% genetically set. A level of 125 nmol/L (50 mg/dL) or more is a risk-enhancing factor; at least 1 in 5 people have elevated levels.
Should healthy adults get their vitamin D tested?
Not routinely. The USPSTF found insufficient evidence to assess vitamin D screening in adults without symptoms (2021), and the Endocrine Society's 2024 guideline suggests against routine 25-hydroxyvitamin D testing. Testing still makes sense if a doctor suspects deficiency.
Are multi-cancer early detection blood tests worth it?
Not as a routine test yet. None is FDA-approved as of mid-October 2026, though an FDA panel backed GRAIL's Galleri test in September. In the NHS-Galleri trial of 142,250 adults, screening didn't significantly reduce stage III or IV cancers, and in PATHFINDER 2 the test found about 4 in 10 cancers. It doesn't replace standard screening.
The Bottom Line

Fewer tests, chosen well.

After 40, the best-backed blood tests are unglamorous: cholesterol, blood sugar, a one-off hepatitis C and HIV check, and kidney tests if you have diabetes or high blood pressure. Add a once-in-a-lifetime Lp(a), and apoB, hs-CRP, iron or B12 when your situation calls for it.

Routine vitamin D, testosterone, thyroid and multi-cancer tests in people who feel well haven't been shown to improve health. Ask your doctor what each result would change.

Sources

  1. US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (clinician summary). 23 August 2022.
  2. Centers for Disease Control and Prevention. Getting Your Cholesterol Checked.
  3. American Heart Association. 2026 Guideline on the Management of Dyslipidemia: Top Things to Know. Guideline published in Circulation online 13 March 2026 (doi:10.1161/CIR.0000000000001423). See also the American College of Cardiology summary.
  4. Quest Diagnostics. Understanding the new dyslipidemia guidelines.
  5. Hoover L. Cholesterol Management: ACC/AHA Updates Guideline. American Family Physician 2019;99(9):589–591 (summary of the 2018 AHA/ACC multisociety cholesterol guideline).
  6. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile (EAS/EFLM joint consensus). European Heart Journal 2016. As summarised by the American College of Cardiology.
  7. US Preventive Services Task Force. Prediabetes and Type 2 Diabetes: Screening. 24 August 2021.
  8. American Diabetes Association. Diagnosis.
  9. US Preventive Services Task Force. Hepatitis C Virus Infection in Adolescents and Adults: Screening. 2 March 2020.
  10. US Preventive Services Task Force. Human Immunodeficiency Virus (HIV) Infection: Screening. 11 June 2019 (update in progress).
  11. KDIGO. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: summary of recommendations and practice points.
  12. American College of Cardiology. UACR Screening During a Routine Annual Visit. 8 June 2026 (summarising ADA Standards of Care 2026, KDIGO 2024 and the 2025 hypertension guideline).
  13. US Preventive Services Task Force. Prostate Cancer: Screening. 8 May 2018 (update in progress).
  14. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal 2022;43(39):3925–3946.
  15. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology 2024.
  16. HCPLive. Expert insights: Lp(a) and apoB in the 2026 dyslipidemia guidelines.
  17. TCTMD. ACC: It's Time for Clinicians to Address Inflammation in CVD. 3 October 2025 (on the ACC scientific statement published in JACC 29 September 2025).
  18. Kowdley KV, Brown KE, Ahn J, Sundaram V. ACG Clinical Guideline: Hereditary Hemochromatosis. American Journal of Gastroenterology 2019;114(8):1202–1218 (doi:10.14309/ajg.0000000000000315).
  19. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1):S183–S215.
  20. NIH Office of Dietary Supplements. Vitamin B12: Fact Sheet for Health Professionals.
  21. US Preventive Services Task Force. Vitamin D Deficiency in Adults: Screening. 13 April 2021.
  22. Endocrine Society. Endocrine Society recommends healthy adults take the recommended daily allowance of vitamin D. 3 June 2024.
  23. American Society for Clinical Pathology Choosing Wisely recommendations, as reported by Bio-Rad QCNet.
  24. Endocrine Society. Experts issue recommendations to improve testosterone prescribing practices. 17 March 2018.
  25. American Urological Association. AUA releases new clinical guideline for diagnosis and treatment of testosterone deficiency. 10 April 2018; guideline page (validity confirmed 2024).
  26. US Preventive Services Task Force. Thyroid Dysfunction: Screening. 24 March 2015.
  27. American Cancer Society. Multi-cancer Early Detection Tests. Last revised 2 October 2025.
  28. GRAIL. FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test. 23 September 2026; and Oncology Nursing News (27 September 2026).
  29. Fierce Biotech. ESMO: Grail eyes FDA review with boosted performance data from Galleri cancer blood test. 20 October 2025 (PATHFINDER 2 results).
  30. Sasieni P, Johnson P, Round T, et al. NHS-Galleri trial. New England Journal of Medicine, published online 22 September 2026 (doi:10.1056/NEJMoa2505723). As reported by the Oncology Learning Network.
  31. National Cancer Institute, Division of Cancer Prevention. Vanguard Study.
  32. Phillips P. Pitfalls in interpreting laboratory results. Australian Prescriber 2009;32(2):43–46.
  33. HealthCare.gov. Preventive care benefits for adults.